The genomic signature of resistance to platinum-containing neoadjuvant therapy based on single-cell data.

Autor: Sui, Qihai¹ (AUTHOR), Hu, Zhengyang¹ (AUTHOR), Jin, Xing¹ (AUTHOR), Bian, Yunyi¹ (AUTHOR), Liang, Jiaqi¹ (AUTHOR), Zhang, Huan¹ (AUTHOR), Yang, Huiqiang¹ (AUTHOR), Lin, Zongwu¹ (AUTHOR), Wang, Qun¹ (AUTHOR) zcchen13@fudan.edu.cn, Zhan, Cheng¹ (AUTHOR) czhan10@fudan.edu.cn, Chen, Zhencong¹ (AUTHOR) wang.qun@zs-hospital.sh.cn

Publikováno v: Cell & Bioscience. 6/8/2023, Vol. 13 Issue 1, p1-16. 16p.

Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.

Autor: Langer CJ; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA., Millenson M, O'Dwyer P, Kosierowski R, Alexander R, Litwin S, McAleer CA, Bonjo CA, Ozols R

Publikováno v: Seminars in oncology [Semin Oncol] 1996 Dec; Vol. 23 (6 Suppl 16), pp. 35-41.

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

Autor: Langer CJ; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA., Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 1995 Aug; Vol. 13 (8), pp. 1860-70.

Paclitaxel by 24- or 1-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: The Fox Chase Cancer Center experience: Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA et al. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111. Semin Oncol 1995;22:Suppl 9:18–29

Publikováno v: In Lung Cancer 1996 14(1):172-172

COX-2/PTGS2-targeted herbal-derived oligonucleotide drug HQi-sRNA-2 was effective in spontaneous mouse lung cancer model.

Autor: Lin Y; State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Sun N; State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Liu D; State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Yang X; State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Dong Y; State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Jiang C; State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Publikováno v: IUBMB life [IUBMB Life] 2024 Nov; Vol. 76 (11), pp. 937-950. Date of Electronic Publication: 2024 Jul 25.